Mantle Cell Lymphoma

Tycel Phillips, MD, discusses updated findings from a phase 1/2 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma.

Frontline treatment with acalabrutinib and bendamustine/rituximab (BR) improved PFS over BR alone in older patients with mantle cell lymphoma.

The combination of zanubrutinib, obinutuzumab, and venetoclax was safe and well-tolerated in older patients with untreated mantle cell lymphoma.

Clinically meaningful activity was found across all subgroups in a posthoc subgroup analysis of patients with MCL treated with liso-cel.

Here is your guide to important regulatory approvals made by the FDA in May 2024.

The FDA approved liso-cel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma after at least 2 prior lines of therapy, including a BTK inhibitor.

The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.

CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.

Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.

Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.

Real-world treatment with zanubrutinib was linked to longer treatment persistence, duration, and time to discontinuation in mantle cell lymphoma.

B-cell receptor signaling characteristics were associated with worse outcomes in patients with mantle cell lymphoma.

Catherine C. Coombs, MD, discusses the mechanism of action of noncovalent BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, discusses the implementation of CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma.

CTL019 CAR T-cell therapy plus time-limited ibrutinib resulted in high complete response rates in relapsed/refractory mantle cell lymphoma.

Tycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.

Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma.

Andre Goy, MD, discusses updated data from the phase 2 ZUMA-2 trial, highlighting the expanded-access ZUMA-18 study in MCL.

A matching-adjusted indirect comparison shows that brexu-cel is superior to pirtobrutinib regarding response and survival in relapsed/refractory MCL.

TP53 mutation and EZH2 expression negatively affect outcomes in mantle cell lymphoma, with a synergistic negative effect.

The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies

Tycel Phillips, MD, discusses efforts to clarify and refine the treatment paradigm of patients with mantle cell lymphoma.

Tycel Phillips, MD, discusses unmet needs for patients with relapsed/refractory mantle cell lymphoma.

Andre H. Goy, MD, discusses how the ZUMA-18 trial data support the benefit of earlier-line use of brexucabtagene autoleucel in mantle cell lymphoma.

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.